Atyr Pharma Inc (ATYR) Stock Price, Quote & News

Company Profile

aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States. Its lead therapeutic candidate efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for the treatment of pulmonary sarcoidosis; Phase 2 clinical trial to treat Sarcoidosis and systemic sclerosis- interstitial lung disease (ILDs); and treatment...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 731 8389

Fax: 858 731 8394

Website: atyrpharma.com

Address:

10240 Sorrento Valley Road, Suite 300, San Diego, United States

trader2sde Apr. 4 at 10:20 PM

$ATYR this was not available in summer 2025...

0 · Reply

trader2sde Apr. 4 at 10:16 PM

$ATYR PRASAD is OUT finally and Senator Johnson investigating the FDA for its failures reg orphan drugs approval. ATYR chances are much better NOW than last summer. also much cheaper lol stock

0 · Reply

nobodyyk Apr. 4 at 9:30 PM

$IXHL $ATYR recieved fast track and look how garbage their p3 was. FTD means nothing at this stage. Joel needs to put his money where his mouth is and show his investors how clear and strong his data is. Instead of playing this vague game.

0 · Reply

trader2sde Apr. 4 at 6:43 PM

$ATYR reminder....

0 · Reply

trader2sde Apr. 4 at 1:16 PM

$ATYR

0 · Reply

trader2sde Apr. 4 at 1:15 PM

$ATYR reminder mid april big meeting with FDA. we ll have to wait a few weeks maximum to learn the results...

0 · Reply

andreassss Apr. 2 at 4:46 PM

$ATYR no volume

0 · Reply

trader2sde Apr. 2 at 2:46 PM

$ATYR reminder... pipeline

1 · Reply

bob397 Apr. 2 at 2:25 PM

$ATYR Financial Review: Silo Pharma (NASDAQ:SILO) and aTyr Pharma (NASDAQ:ATYR) - American Market News https://www.americanbankingnews.com/2026/04/02/financial-review-silo-pharma-nasdaqsilo-and-atyr-pharma-nasdaqatyr.html

0 · Reply

trader2sde Apr. 1 at 5:27 PM

$ATYR Japan big market NEED alternative to steroids for pulmonary sarcoidosis... duh...

0 · Reply

Ethos to Announce First Quarter 2026 Financial Results on May 6, 2026

LIFE

Mar 24, 2026, 4:05 PM EDT - 11 days ago

Ethos and Banner Life Expand Offering to Bring Final Expense Coverage to More Families

LIFE

Mar 5, 2026, 4:01 PM EST - 4 weeks ago

aTyr Pharma Announces Fourth Quarter and Full Year 2025 Results and Provides Corporate Update

Feb 26, 2026, 4:06 PM EST - 5 weeks ago

Ethos to Participate in The Citizens Technology Conference

LIFE

Feb 25, 2026, 10:27 PM EST - 5 weeks ago

Ethos Technologies Inc. (LIFE) Q3 2026 Earnings Call Transcript

LIFE

Feb 25, 2026, 4:05 PM EST - 5 weeks ago

Ethos Reports Fourth Quarter and Fiscal Year 2025 Financial Results

LIFE

Feb 20, 2026, 4:01 PM EST - 6 weeks ago

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 18, 2026, 8:00 AM EST - 6 weeks ago

aTyr Pharma to Present at the Leerink Partners Global Healthcare Conference

Feb 5, 2026, 4:05 PM EST - 2 months ago

Ethos to Announce Fourth Quarter 2025 Financial Results on February 25, 2026

LIFE

Feb 3, 2026, 2:46 PM EST - 2 months ago

The IPO Market Faces a Busy Week. These Stocks Are Making Their Debuts.

FPS LFTO YSS

Feb 3, 2026, 8:00 AM EST - 2 months ago

aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis

Jan 30, 2026, 10:25 PM EST - 2 months ago

U.S. IPO Weekly Recap: Trio Of Sizable Listings Underwhelm To Close Out January

AGMB BOBS EIKN FPS LFTO OFRM OPTN

Jan 30, 2026, 12:21 AM EST - 2 months ago

Ethos Technologies: A Surprisingly Soft Debut

Jan 29, 2026, 12:30 PM EST - 2 months ago

Insurance platform Ethos Technologies valued at $1.2 billion in Nasdaq debut

Jan 28, 2026, 10:38 PM EST - 2 months ago

Ethos Announces Pricing of Initial Public Offering

Jan 28, 2026, 9:05 PM EST - 2 months ago

Ethos Technologies prices US IPO at $19/share, Bloomberg News reports

Jan 23, 2026, 10:45 PM EST - 2 months ago

U.S. IPO Weekly Recap: Equipment Rental Rises While Crypto Company Crashes In 2-IPO Week

BTGO EQPT PICS PPHC YSS CLRS

Jan 7, 2026, 8:01 AM EST - 3 months ago

Ethos and North American Collaborate to Offer Accumulation Indexed Universal Life Product

Jan 2, 2026, 10:35 PM EST - 3 months ago

U.S. IPO Weekly Recap: Small Issuers And SPACs Join The Pipeline In Short Holiday Week

OXY BTGO EQPT GRAY IBL KLK MMED

Dec 18, 2025, 8:01 AM EST - 3 months ago

Ethos and Aflac Partner to Bring Supplemental Health Product Suite to Independent Distribution

Dec 15, 2025, 2:45 PM EST - 3 months ago

Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders

Dec 8, 2025, 3:25 AM EST - 4 months ago

aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - ATYR

Dec 7, 2025, 9:02 AM EST - 4 months ago

ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 6, 2025, 12:58 PM EST - 4 months ago

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

Dec 4, 2025, 10:56 AM EST - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 3, 2025, 4:21 PM EST - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Lawsuit – ATYR

Dec 3, 2025, 9:22 AM EST - 4 months ago

ATYR INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Dec 1, 2025, 6:32 PM EST - 4 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma

Nov 26, 2025, 11:34 AM EST - 4 months ago

The Short List — Top 10 Most Shorted Stocks Right Now

HIMS HTZ LCID NTLA REPL SOC WEN

Nov 25, 2025, 4:08 PM EST - 4 months ago

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug's Efficacy Moves Forward -- Hagens Berman

Nov 20, 2025, 8:45 AM EST - 4 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of December 8, 2025 in aTyr Pharma, Inc. Lawsuit - ATYR

Nov 18, 2025, 2:03 PM EST - 4 months ago

ATYR INVESTOR NOTICE: New aTyr Pharma, Inc. (ATYR) Securities Class Filed; Class Period Significantly Enlarged -- Hagens Berman

Nov 11, 2025, 9:23 AM EST - 5 months ago

aTyr Pharma, Inc. (ATYR) Failed Drug Trial Spurs Securities Lawsuit; Class Period Significantly Enlarged -- Hagens Berman

Nov 10, 2025, 8:00 AM EST - 5 months ago

aTyr Pharma to Present at Piper Sandler 37th Annual Healthcare Conference

Nov 6, 2025, 4:01 PM EST - 5 months ago

aTyr Pharma Announces Third Quarter 2025 Results and Provides Corporate Update

trader2sde Apr. 4 at 10:20 PM

$ATYR this was not available in summer 2025...

0 · Reply

trader2sde Apr. 4 at 10:16 PM

$ATYR PRASAD is OUT finally and Senator Johnson investigating the FDA for its failures reg orphan drugs approval. ATYR chances are much better NOW than last summer. also much cheaper lol stock

0 · Reply

nobodyyk Apr. 4 at 9:30 PM

0 · Reply

trader2sde Apr. 4 at 6:43 PM

$ATYR reminder....

0 · Reply

trader2sde Apr. 4 at 1:16 PM

$ATYR

0 · Reply

trader2sde Apr. 4 at 1:15 PM

$ATYR reminder mid april big meeting with FDA. we ll have to wait a few weeks maximum to learn the results...

0 · Reply

andreassss Apr. 2 at 4:46 PM

$ATYR no volume

0 · Reply

trader2sde Apr. 2 at 2:46 PM

$ATYR reminder... pipeline

1 · Reply

bob397 Apr. 2 at 2:25 PM

0 · Reply

trader2sde Apr. 1 at 5:27 PM

$ATYR Japan big market NEED alternative to steroids for pulmonary sarcoidosis... duh...

0 · Reply

ClearCities Apr. 1 at 4:55 PM

$ATYR In most cases for a BO in biotech, Big Pharma's take peak sales of the drug x 1.5-2. If that's the case, 750Mil to 1Bil MC would make this 76sp - 101sp with current 98.08 Mil OS. The numbers sound unreasonable and not correct rn obviously as the drug is not approved. Just saying the equation Big Pharma bases off for a BO /. I presume at least a 3-4 dollars here

2 · Reply

ClearCities Apr. 1 at 4:50 PM

$ATYR Pulmonary Sarcoidosis alone has a peak sales of 500Mil for Efitzomod. Theer is no way wallst or Big Pharma will throw this away, not to mention drug has not been renewed for the past 60 yrs

0 · Reply

Jmdouk2 Apr. 1 at 4:37 PM

$ATYR let’s go!! been waiting for this to wake up!! may this be the month!!

2 · Reply

trader2sde Apr. 1 at 2:03 PM

$ATYR institutionals looking for high returns rare spots... they avoid space (space X numerous explosions completely changes the prospect for gravitating companies), private credit!! ( cars students AI , ALL), quantum, softwares, airliners etc etc... lots of sectors to avoid... ATYR is a rare spot where institutionals STILL kept their positions and added and are adding imho...

1 · Reply

trader2sde Mar. 31 at 9:40 PM

$ATYR institutionals back in... ( spikes)

0 · Reply

andreassss Mar. 31 at 2:18 PM

$ATYR is there a date for the outcome of compliance?

2 · Reply

trader2sde Mar. 31 at 1:36 PM

$ATYR

0 · Reply

Indialli1309 Mar. 31 at 8:28 AM

$ATYR volume seems increasing🤔

0 · Reply

trader2sde Mar. 30 at 7:50 PM

$ATYR

0 · Reply

trader2sde Mar. 30 at 5:56 PM

$ATYR Germans are watching ATYR.... https://www.ad-hoc-news.de/boerse/news/ueberblick/atyr-pharma-shares-in-a-holding-pattern-amid-quiet-period/69028357

0 · Reply

alexx013 Mar. 30 at 2:56 PM

$ATYR added .73

0 · Reply

trader2sde Mar. 30 at 3:39 AM

$ATYR

0 · Reply

Market Cap	83.04M
Revenue (ttm)	190,000.00
Net Income (ttm)	-74.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39,010.53%
Debt to Equity Ratio	0.00

Volume	704,000
Avg Vol	1,801,642
Day's Range	N/A - N/A
Shares Out	98.05M
Stochastic %K	85%
Beta	0.64
Analysts	Sell
Price Target	$4.50